Global Industrial Bioprocessing Market Size study, by Workflow (Downstream, Upstream), by Product, by Use Type, by Mode (In-house, Outsourced) and Regional Forecasts 2022-2032

Global Industrial Bioprocessing Market is valued approximately at USD 70.74 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 13.80% over the forecast period 2024-2032. Industrial bioprocessing stands as a keystone in modern bio-manufacturing, where biologically-driven mechanisms replace traditional chemical-based processes for producing goods such as biopharmaceuticals, food ingredients, biofuels, and industrial enzymes. Harnessing the potential of microbial and cellular systems, this industry operates at the intersection of sustainability, innovation, and efficiency. The upstream segment, which includes cell culture, fermentation, and media development, is undergoing transformation through automated bioreactor systems and data-driven process optimization, while downstream processes are integrating high-throughput purification and real-time quality monitoring to maximize yield and product purity. This convergence of biotechnology and industrial scalability is unlocking new commercial pathways for biologics production at lower costs and reduced ecological footprints.

Surging demand for biologics, biopharmaceuticals, and enzyme-based industrial products across pharmaceuticals, food & beverages, and chemicals sectors is among the foremost growth stimulants in this space. Organizations across the globe are aggressively pursuing green alternatives to reduce reliance on petrochemicals, creating fertile ground for bio-based processing innovations. Additionally, global initiatives promoting bioeconomy, including significant public-private partnerships and government-funded bioprocess innovation hubs, are accelerating technology commercialization. For example, the BioMADE initiative in the U.S. and Bio-based Industries Joint Undertaking in the EU are channeling billions into R&D and pilot-scale production facilities. However, the sector grapples with challenges such as scale-up complexities, regulatory hurdles, and the substantial initial capital investments required for bioprocess equipment and validation.

Moreover, the proliferation of single-use technologies, AI-powered bioprocess control systems, and modular manufacturing units is reshaping how bioprocessing facilities are designed and operated. These innovations are enabling flexible, small-batch production environments that can rapidly respond to shifting market demands, particularly in personalized medicine and niche bio-product segments. Outsourced bioprocessing models are also on the rise, driven by biotech startups and mid-sized enterprises lacking infrastructure or regulatory expertise, prompting the growth of CDMOs (Contract Development and Manufacturing Organizations). Simultaneously, in-house process automation with integrated digital twins and predictive analytics is helping large enterprises minimize downtime, optimize yield, and shorten product development timelines.

As a result, the competitive landscape is evolving quickly, with both legacy industrial manufacturers and emerging biotech players vying for market share through mergers, strategic alliances, and technology licensing deals. Industry leaders are strategically investing in vertically integrated platforms to control every node of the bioprocessing value chain—from raw materials sourcing and upstream development to downstream purification and packaging. Furthermore, end-use diversification across agriculture, cosmetics, and environmental sectors is broadening the market’s commercial scope beyond conventional pharmaceuticals and food industries. This diversification is helping companies mitigate risk and maintain stability amid regulatory fluctuations and pricing pressures.

Geographically, Europe dominated the market in 2023, buoyed by strong regulatory frameworks promoting bio-manufacturing, extensive R&D infrastructure, and a well-established pharmaceutical production base. The region’s emphasis on circular economy principles and green industrial policies further accelerates the deployment of bioprocess technologies. Meanwhile, Asia Pacific is poised to witness the fastest growth over the forecast period due to expanding biopharma manufacturing hubs in countries like China, India, and South Korea, alongside increasing government incentives and foreign direct investment. North America remains a stronghold for bioprocess innovation, with an abundance of biotech startups and significant capital inflows, particularly in gene therapy and personalized medicine production segments.

Major market player included in this report are:
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• GE HealthCare
• Sartorius AG
• Eppendorf AG
• Boehringer Ingelheim International GmbH
• Lonza Group AG
• Fujifilm Diosynth Biotechnologies
• Repligen Corporation
• Cytiva
• Corning Incorporated
• Nova Biomedical Corporation
• Applikon Biotechnology BV
• MilliporeSigma

The detailed segments and sub-segment of the market are explained below:

By Workflow
• Upstream
• Downstream

By Product
• Bioreactors
• Filtration Systems
• Centrifuges
• Consumables
• Others

By Use Type
• Research & Development
• Commercial

By Mode
• In-house
• Outsourced

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.